---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-064309"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2024-05-24T23:59:59+00:00"
generated_at: "2026-06-01T08:54:49.850693+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CG Oncology reports 54% CR at 24 months for cretostimogene combo in NMIBC

## Summary
- Phase 2 CORE-001 final results: 54% (19/35) complete response rate at 24 months in BCG-unresponsive HR-NMIBC with CIS.
- Median duration of response exceeds 21 months; 95% of 12-month CR patients maintained CR for another 12 months.
- Progression-free survival at 24 months was 100%; cystectomy-free survival at 24 months was 80% (100% for CR patients).
- No synergistic toxicity observed; combination with pembrolizumab well tolerated.
- FDA Breakthrough Therapy Designation granted in May 2023; company plans to incorporate findings into planned CORE-008 trial.

## SEC filing metadata
- accession: 0000950170-24-064309
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2024-05-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000095017024064309/0000950170-24-064309-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000095017024064309/ck0001991792-20240524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-064309
- JSON: https://secwatch.observer/filing/0000950170-24-064309.json
- Plain text: https://secwatch.observer/filing/0000950170-24-064309.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.